Biogen market cap BIIB

Share price times shares outstanding: what the whole company sells for, since 2009.

Biogen is worth $37B at the close on Oct 23, 2026, at $250.69 a share.

That is up 69% over the last year and down 5% over five years.

Its highest close in our data was $111.7B in Mar 2015.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$37B	$24.1B	$37B	+43%
2025	$26B	$16.9B	$26.7B	+18%
2024	$22B	$21.3B	$37.4B	−41%
2023	$37.5B	$32.6B	$46B	−6%
2022	$39.9B	$28.4B	$43.9B	+13%
2021	$35.2B	$32.9B	$59.7B	−6%
2020	$37.7B	$37.2B	$59.6B	−30%
2019	$54.1B	$40.5B	$68B	−8%
2018	$59.1B	$54.5B	$77.8B	−12%
2017	$67.4B	$53B	$71.5B	+9%
2016	$61.7B	$50.2B	$69.4B	−10%
2015	$68.3B	$61.7B	$111.7B	−16%
2014	$80.9B	$64.8B	$85.2B	+24%
2013	$65.5B	$34B	$68.7B	+89%
2012	$34.6B	$27.8B	$36.5B	+29%
2011	$26.7B	$15.5B	$28.8B	+67%
2010	$16B	$12.3B	$16.2B	+3%
2009	$15.5B	$12.2B	$15.5B	n/a

Companies in Drug Manufacturers - General nearest Biogen's size, closest first, today.

Company	Market cap
BIIBBiogen	$37B
JAZZJazz Pharmaceuticals	$13.9B
BMYBristol-Myers Squibb	$125.6B
BMRNBiomarin Pharmaceutical	$10.8B
CORTCorcept Therapeutics	$9.3B
PTGXProtagonist Therapeutics	$9B
TGTXTG Therapeutics	$8.3B
PFEPfizer	$171.2B
ALKSAlkermes plc.	$7.3B
GILDGilead Sciences	$193.5B
AMRXAmneal Pharmaceuticals	$6.5B
Peer median	$10.1B